Sanofi and Regeneron to Present Results from Phase 3 Praluent® (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2015

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. APGE
5. MU
6. GOOGL
7. HOOD
8. DFTX
9. MSTR
10. ABBV

Go back to Sanofi and Regeneron to Present Results from Phase 3 Praluent® (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2015

Leerink Partners Reiterated Outperform Following Regeneron's (REGN) 3Q Beat

November 5, 2015 8:07 AM EST

Leerink Partners reiterated an Outperform rating and $664.00 price target on Regeneron Pharma (NASDAQ: REGN) following the company's 3Q earnings report. REGN reported revenues and EPS of $1.14bn and $1.82, respectively, thereby beating consensus estimates of $1.79 and $1.64. REGN tightened its 2015 non-GAAP R&D guidance... More